News 07.01.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in...
News 05.01.2024 Zurich-Schlieren, Switzerland, January 5th, 2024 Swiss biotech start-up Topadur Pharma AG is pleased to announce that it has been awarded a Start-up Innovation Project grant from Innosuisse. With this funding, Innosuisse is supporting a Proof-of-Concept, Phase 2a clinical trial in patients with digital ulcers (DU) in systemic sclerosis (SSc).The grant of...
News 04.01.2024 Zurich-Schlieren, Switzerland, 20 December 2023 Swiss Topadur Pharma AG, in collaboration with South Korean Juvic Inc. and the research group led by Prof. Hyungil Jung at Yonsei University in Seoul, has launched a project to improve disease management in systemic sclerosis. The project particularly aims to enhance treatment for patients who...
News 04.01.2024 Schlieren (Zurich), Switzerland, January 4, 2024 – Kuros Biosciences, a leader in next generation bone graft technologies, announced today three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a real world patient population in...
News 27.12.2023 Schlieren (Zurich), Switzerland, December 27, 2023 – Kuros Biosciences, a leader in next generation bone graft technologies, today announced results from two prospective, randomized clinical studies – the STRUCTURE and MAXA trials. In the MAXA trial, MagnetOs showed a 73% higher fusion rate relative to autograft in the challenging posterolateral...